



## BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020

November 3, 2020

**Mainz, Germany, November 3, 2020 (GLOBE NEWSWIRE)** – [BioNTech SE](#) (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2020 on Tuesday, November 10<sup>th</sup>, 2020. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 08:00 a.m. EDT (2:00 p.m. CET) to report its financial results and provide a corporate update on the third quarter 2020.

The slide presentation and audio of the webcast will be available via the following link: <https://edge.media-server.com/mmc/p/jqhpoczuz>

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

United States international: +1 646 741 3167

United States domestic (toll-free): +1 877 870 9135

Germany: +49 (0) 692 2222 625

Conference ID: 5356399

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at <https://biontech.de/>. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

### About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### BioNTech Contacts

#### Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

[Investors@biontech.de](mailto:Investors@biontech.de)

#### Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513 or +49 (0)151 1978 1385

[Media@biontech.de](mailto:Media@biontech.de)